CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

Clin Pharmacol Ther. 2006 Jun;79(6):511-20. doi: 10.1016/j.clpt.2006.03.008.
No abstract available

MeSH terms

  • Acenocoumarol / administration & dosage
  • Acenocoumarol / adverse effects*
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Blood Coagulation Disorders / chemically induced
  • Blood Coagulation Disorders / epidemiology
  • Blood Coagulation Disorders / genetics*
  • Cost-Benefit Analysis
  • Cytochrome P-450 CYP2C9
  • Genotype
  • Humans
  • International Normalized Ratio / economics*
  • Models, Statistical
  • Netherlands / epidemiology

Substances

  • Anticoagulants
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Acenocoumarol